Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow
C W
CW
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Mytilineou
C
C
Tatton
W
W
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D012642:Selegiline